Latest Breaking News On - Sarah boyce - Page 1 : vimarsana.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $41.33 Consensus PT from Brokerages

Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last […]

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Rating of "Buy" by Brokerages

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last year is […]

Avidity Biosciences (NASDAQ:RNA) Releases Earnings Results, Beats Expectations By $0.02 EPS

Avidity Biosciences (NASDAQ:RNA – Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.02, Zacks reports. Avidity Biosciences had a negative net margin of 2,103.78% and a negative return on equity of 37.98%. The company had revenue of […]

Avidity Biosciences (NASDAQ:RNA) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Avidity Biosciences (NASDAQ:RNA – Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.02, Zacks reports. The company had revenue of $3.54 million during the quarter, compared to analyst estimates of $7.09 million. Avidity Biosciences had […]

Chardan Capital Reiterates "Buy" Rating for Avidity Biosciences (NASDAQ:RNA)

Highlights from the Django Developer Survey 2024

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

Delpacibart Etedesiran Gets Breakthrough Tx Status for Myotonic Dystrophy Type 1

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Average Rating of "Buy" by Brokerages

Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have received an average recommendation of “Buy” from the six ratings firms that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have updated their coverage on the stock […]

abrdn plc Purchases New Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

abrdn plc acquired a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 129,414 shares of the biotechnology company’s stock, valued at approximately $1,171,000. Other hedge funds and other institutional investors also recently made changes to their positions in the company. Adage Capital […]